Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Melanoma (Skin): early-phase trial registry
7 of 54 indexed Melanoma (Skin) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #261 of 28,707 conditions by registered trial count.
54 US clinical trials · 7 currently recruiting · #261 of 28,707 conditions by registered trial count
Melanoma (Skin): 54 US clinical trials tracked, 7 recruiting.
Melanoma (Skin) is the subject of 54 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 49 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 10 of these trials.
Enrollment posture brief
Registry condition melanoma-skin
OPEN 7 | RECR 13% | LATE 1 | EARLY 49 | RANK #261 | SPON 10
Volume-matched condition peers
Nearest open-share peer: Myocardial Ischemia (13% recruiting · 31 trials)
Melanoma (Skin) lists 7 open slots (13% of 54 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Melanoma (Skin) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Melanoma (Skin) is recruiting below its size-band peers.
7 of 54 indexed trials (13%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Melanoma (Skin) research.
National Cancer Institute (NCI) accounts for 10 of 54 trials (18.5%). 33 distinct sponsors appear on at least one study for this condition label.
-
Most Melanoma (Skin) trials plan to enrol fewer than 100 people.
Median target enrolment is 35 among the 31 trials that report a genuine target (sentinel values excluded). 23 of those (74.2%) plan for fewer than 100 participants.
-
Melanoma (Skin) research is mostly interventional.
53 interventional and 1 observational studies make up this index (98.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
54 total, page 1 of 2
Rural Adult and Youth Sun Protection Study
University of Utah
NCT06439979
Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
University of Texas Southwestern Medical Center
NCT06400550
DermaSensor Postmarket Surveillance Study
DermaSensor
NCT06666790
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Hummingbird Bioscience
NCT06956690
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
Dana-Farber Cancer Institute
NCT06298734
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
M.D. Anderson Cancer Center
NCT05704647
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
University of California, Irvine
NCT06771544
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
ECOG-ACRIN Cancer Research Group
NCT00003641
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT03543969
Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma
National Institutes of Health Clinical Center (CC)
NCT00077532
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
Craig L Slingluff, Jr
NCT00118274
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
H. Lee Moffitt Cancer Center and Research Institute
NCT01176461
SWOG-9430: Surgery in Treating Patients With Metastatic Melanoma
SWOG Cancer Research Network
NCT00002860
Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma
University of Southern California
NCT00031733
PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma
Cellxpert Biotechnology
NCT00073892
Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma
University of Utah
NCT04062032
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Alliance for Clinical Trials in Oncology
NCT00017121
Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery
Memorial Sloan Kettering Cancer Center
NCT00004250
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
Memorial Sloan Kettering Cancer Center
NCT00398073
Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma
Jonsson Comprehensive Cancer Center
NCT00471887
Vaccine Therapy in Treating Patients With Metastatic Melanoma
University of Virginia
NCT00003224
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Pawel Kalinski
NCT00390338
Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma
Dartmouth-Hitchcock Medical Center
NCT00085423
Biological Therapy in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
NCT00002786
Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma
University of Chicago
NCT00002952
Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg
Duke University
NCT00565968
Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
Rutgers, The State University of New Jersey
NCT00962845
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
Memorial Sloan Kettering Cancer Center
NCT00104845
Vaccine Therapy in Treating Patients With Melanoma
National Cancer Institute (NCI)
NCT00003556
Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer
Northwestern University
NCT00276835
Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin
University of Oklahoma
NCT00453050
Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00003802
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
Eastern Cooperative Oncology Group
NCT00003308
Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
NCT00079144
Vaccine Therapy in Treating Patients With Stage IV Melanoma
SWOG Cancer Research Network
NCT00042783
Vaccine Therapy in Treating Patients With Metastatic Cancer
National Cancer Institute (NCI)
NCT00021164
Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
NCT00072085
Vaccine Therapy in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
NCT00019994
Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma
Fred Hutchinson Cancer Center
NCT00006233
Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
National Cancer Institute (NCI)
NCT00020540
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment
National Cancer Institute (NCI)
NCT00022438
Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma
National Human Genome Research Institute (NHGRI)
NCT00005057
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma
National Cancer Institute (NCI)
NCT00019175
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Memorial Sloan Kettering Cancer Center
NCT00005633
Biological Therapy in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
NCT00045149
Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
Eastern Cooperative Oncology Group
NCT00006385
Gene Therapy in Treating Patients With Metastatic Melanoma
University of Colorado, Denver
NCT00005943
Irofulven in Treating Patients With Stage IV Melanoma
University of Colorado, Denver
NCT00005968
Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal
Duke University
NCT00003229
Vaccine Therapy in Treating Patients With Melanoma
National Cancer Institute (NCI)
NCT00020358
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 27 |
| Phase 2 | 22 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Melanoma (Skin) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Melanoma (Skin) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Melanoma (Skin) page
54 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Melanoma (Skin) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Melanoma (Skin) trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Melanoma (Skin) condition card totals 54 registered trials; most-linked intervention aldesleukin; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.